Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory T cells in Cynomolgus macaque

Ellis, Gavin I.; Coker, Kimberly E.; Winn, Delaine W.; Deng, Mosha Z.; Shukla, Divanshu; Bhoj, Vijay; Milone, Michael C.; Wang, Wei; Liu, Chengyang; Naji, Ali; Duran‐Struuck, Raimon; Riley, James L.

doi:10.1016/j.xcrm.2022.100614

Cited by 12 publications

(13 citation statements)

References 81 publications

(105 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our hands, K562-based aAPC stimulation results in larger T cell numbers versus bead-based stimulation ( Ellis et al., 2022 ; Hippen et al., 2008 , 2011 ; Maus et al., 2002 ; Suhoski et al., 2007 ; Thomas et al., 2002 ; Ye et al., 2011 ). We have used these cells successfully to stimulate Cynomolgus macaque ( Ellis et al., 2022 ) and Rhesus macaque ( Rust et al., 2020 ) T cells. Begin expansion of K562.F12Q.86 and K562.Bw6.86 cells.…”

Section: Before You Beginmentioning

confidence: 60%

“…The aAPCs used here were generated by transducing K562 cells with both α-CD3 CAR and human CD86 lentiviral vectors (K562.F12Q.86) or with HLA-B7 (Bw6+) and human CD86 vectors (K562.Bw6.86), performing single cell sorting of double positive clones, and characterizing the stability of transgene expression over time before selecting an optimal clone ( Ellis et al., 2022 ). In our hands, K562-based aAPC stimulation results in larger T cell numbers versus bead-based stimulation ( Ellis et al., 2022 ; Hippen et al., 2008 , 2011 ; Maus et al., 2002 ; Suhoski et al., 2007 ; Thomas et al., 2002 ; Ye et al., 2011 ). We have used these cells successfully to stimulate Cynomolgus macaque ( Ellis et al., 2022 ) and Rhesus macaque ( Rust et al., 2020 ) T cells.…”

Section: Before You Beginmentioning

confidence: 99%

“…NHP T cells express restriction factors that can reduce transduction efficiency by HIV based lentiviral vectors ( Ellis et al., 2022 ; Hatziioannou et al., 2006 ; Richardson et al., 2014 ; Stremlau et al., 2004 ). Therefore, our simian tropic lentiviral packaging mix contains an HIV-SIV chimeric gag-pol (χHIV) ( Hatziioannou et al., 2006 ; Uchida et al., 2009 ) and are pseudotyped with Cocal virus envelope glycoprotein ( Trobridge et al., 2010 ).…”

Section: Before You Beginmentioning

confidence: 99%

“…The result of this method is highly suppressive CAR Tregs for use in a pre-clinical, large animal model of transplant tolerance. For complete details on the use and execution of this protocol, please refer to Ellis et al. (2022) .…”

mentioning

confidence: 99%

“…For complete details on the use and execution of this protocol, please refer to Ellis et al. (2022) .…”

mentioning

confidence: 99%

See 4 more Smart Citations

Generation of non-human primate CAR Tregs using artificial antigen-presenting cells, simian tropic lentiviral vectors, and antigen-specific restimulation

et al. 2022

Self Cite

View full text Add to dashboard Cite

Section: Before You Beginmentioning

confidence: 60%

Section: Before You Beginmentioning

confidence: 99%

Section: Before You Beginmentioning

confidence: 99%

mentioning

confidence: 99%

“…For complete details on the use and execution of this protocol, please refer to Ellis et al. (2022) .…”

mentioning

confidence: 99%

See 3 more Smart Citations

Generation of non-human primate CAR Tregs using artificial antigen-presenting cells, simian tropic lentiviral vectors, and antigen-specific restimulation

et al. 2022

Self Cite

View full text Add to dashboard Cite

Unlocking Transplant Tolerance with Biomaterials

Pham,

Coronel

2024

Adv Healthcare Materials

View full text Add to dashboard Cite

For patients suffering from organ failure due to injury or autoimmune disease, allogeneic organ transplantation with chronic immunosuppression is considered the gold standard in terms of clinical treatment. However, the true “holy grail” of transplant immunology is operational tolerance, in which the recipient exhibits a sustained lack of alloreactivity toward unencountered antigen presented by the donor graft. This outcome is resultant from critical changes to the phenotype and genotype of the immune repertoire predicated by the activation of specific signaling pathways responsive to soluble and mechanosensitive cues. Biomaterials have emerged as a medium for interfacing with and reprogramming these endogenous pathways towards tolerance in precise, minimally invasive, and spatiotemporally defined manners. By viewing seminal and contemporary breakthroughs in transplant tolerance induction through the lens of biomaterials‐mediated immunomodulation strategies – which include intrinsic material immunogenicity, the depot effect, graft coatings, induction and delivery of tolerogenic immune cells, biomimicry of tolerogenic immune cells, and in situ reprogramming – this review emphasizes the stunning diversity of approaches in the field and spotlights exciting future directions for research to come.This article is protected by copyright. All rights reserved

show abstract